Data as of Apr 17
| +0.38 / +8.80%|
The 2 analysts offering 12-month price forecasts for Pernix Therapeutics Holdings Inc have a median target of 5.15, with a high estimate of 6.30 and a low estimate of 4.00. The median estimate represents a +9.57% increase from the last price of 4.70.
The current consensus among 2 polled investment analysts is to Buy stock in Pernix Therapeutics Holdings Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.